But a sequence is not a drug. Every AI-designed candidate still has to be expressed, screened, validated, assessed for developability and manufactured to a standard that supports IND/CTA-enabling studies. That is where many promising programmes can slow down, and where the right development partner makes the biggest difference.

Score your programme with our AI antibody readiness check